Skip to main content
SpringerLink
Log in

Analogs of Luteinizing Hormone-releasing Hormone in Benign Prostatic Hyperplasia and Advanced Renal Cell Carcinoma

  • Conference paper
Book cover Peptides and Non Peptides of Oncologic and Neuroendocrine Relevance

  • 63 Accesses

Abstract

Benign prostatic hyperplasia (BPH) is a significant health problem all over the world. This condition will affect most men should they live long enough and can lead to serious complications, such as acute or chronic urinary retention, renal insufficiency, urinary tract infection and sexual dysfunction (Oesterling, 1996; Isaacs, 1990). Symptomatic BPH causes morbidity and can lower the quality of life (QoL) (Hoznek and Abben, 2001; Hegarty et al., 2001). We investigated whether short-term administration of the LHRH antagonist cetrorelix could provide a new treatment for men with BPH (Comaru-Schally et al., 1998).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Aoyagi T., Takishima K., Hayakawa M. and Nakamura H. (1996). Gene expression of TGF-α, EGF and IL-6 in cultured renal tubular cells and renal cell carcinoma. Int J Urol, 3, 392–396.

    Article  PubMed  CAS  Google Scholar 

  • Barry M. and Roehrborn C. (1997). Management of benign prostatic hyperplasia. Annu Rev Med, 48, 177–189.

    Article  PubMed  CAS  Google Scholar 

  • Begun F.R, Story M.T., Hopp K.A., Shapiro E. and Lawson R.K. (1995). Regional concentration of basic fibroblast growth factor in normal and benign hyperplastic human prostates. J Urol, 153, 839–843.

    Article  PubMed  CAS  Google Scholar 

  • Cohen P., Peehl D.M., Baker B., Liu F., Hintz R.L. and Rosenfeld R.G. (1994). Insulin-like growth factor axis abnormalities in prostatic stromal cells from patients with benign prostatic hyperplasia. J Clin Endocrinol Metab, 79, 1410–1415.

    Article  PubMed  CAS  Google Scholar 

  • Comaru-Schally A.M., Brannan W., Schally A.V., Colcolough M. and Monga M. (1998). Efficacy and safety of LHRH antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperplasia. J Clin Endocrinol Metab, 83, 3826–3831.

    Article  PubMed  CAS  Google Scholar 

  • Culig Z., Hobisch A., Cronauer M.V., Radmayr C, Hittmair A., Zhang J., Thurnher M., Bartsch G. and Klocker H. (1996). Regulation of prostatic growth and function by peptide growth factors. Prostate, 28, 392–405.

    Article  PubMed  CAS  Google Scholar 

  • De Bellis A., Ghiandi P., Comerci A., Fiorelli G., Grappone C, Milani S., Salerno R., Marra F. and Serio M. (1996). Epidermal growth factor, epidermal growth factor receptor, and transforming growth factor-alpha in human hyperplastic prostate tissue: expression and cellular localization. J Clin Endocrinol Metab, 81, 4148–4154.

    Article  PubMed  CAS  Google Scholar 

  • Dutcher J.P., Fisher R.I., Weiss G., Aronson E, Margolin K., Louie A., Mier J., Caliendo G., Sosman J.A., Eckardt J.R., Ernest M.L., Doroshow J. and Atkins M. (1997). Outpatient subcutaneous interleukin-2 and interferon-α for metastatic renal cell cancer: 5-year follow-up of the Cytokine Working Group Study. Cancer J Sci Am, 3, 157–162.

    PubMed  CAS  Google Scholar 

  • Gabrilove J.L., Levine A.C., Kirschenbaum A., Droller M. (1989). Effect of long-acting gonadotropin-releasing hormone analog (leuprolide) therapy on prostatic size and symptoms in 15 men with benign prostatic hypertrophy. J Clin Endocrinol Metab, 69, 629–632.

    Article  PubMed  CAS  Google Scholar 

  • Godley P. and Kim S.W. (2002). Renal cell carcinoma. Curr Opin Oncol, 14, 280–285.

    Article  PubMed  Google Scholar 

  • Gonzalez-Barcena D., Vadillo-Buenfil M., Gomez-Orta F., Fuentes Garcia M., Cardenas-Cornejo I., Graef-Sanchez A., Comaru-Schally A.M. and Schally A.V. (1994). Responses to the antagonistic analog of LHRH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer. Prostate, 24, 84–92.

    Article  PubMed  CAS  Google Scholar 

  • Hegarty P.K., Hegarty N.J., Fitzpatrick J.M. (2001). Sexual function in patients with benign prostatic hyperplasia. Curr Urol Rep, 2, 292–296.

    Article  PubMed  CAS  Google Scholar 

  • Henriksson R., Nilsson S., Colleen S., Wersau P., Heising M., Zimmerman R. and Engman K. (1998). Survival in renal cell carcinoma-a randomized evaluation of tamoxifen vs. interleukin 2, a-interferon (leucocyte) and tamoxifen. Br J Cancer, 77, 1311–1317.

    Article  PubMed  CAS  Google Scholar 

  • Hoznek A. and Abbou C.C. (2001). Impact of interventional therapy for benign prostatic hyperplasia on quality of life and sexual function. Curr Urol Rep, 2, 311–317.

    Article  PubMed  CAS  Google Scholar 

  • Isaacs J.T. (1990). Importance of the natural history of benign prostatic hyperplasia in the evaluation of pharmacologic intervention. Prostate, 3, 1–7.

    Article  PubMed  CAS  Google Scholar 

  • Jemal A., Thomas A., Murray T. and Thun M. Cancer statistics. (2002). CA Cancer J Clin, 52, 23–47.

    Article  PubMed  Google Scholar 

  • Jungwirth A., Schally A.V., Haimos G., Groot K., Szepeshazi K., Pinski J. and Armatis P. (1998). Inhibition of the growth of Caki-I human renal adenocarcinoma in vivo by LHRH antagonists Cetrorelix, somatostatin analog RC-160 and bombesin antagonist RC-3940-II. Cancer, 82, 909–917.

    Article  PubMed  CAS  Google Scholar 

  • Lepor H., Williford W.O., Barry M.J., Brawer M.K., Dixon CM., Gormley G., Haakenson C, Machi M., Narayan P. and Padley R.J. (1996). The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med, 335, 533–539.

    Article  PubMed  CAS  Google Scholar 

  • McKiernan J.M. and Lowe F.C. (1997). Side effects of terazosin in the treatment of symptomatic benign prostatic hyperplasia. South Med J, 90, 509–513.

    Article  PubMed  CAS  Google Scholar 

  • Motzer R.J., Bander N.H., Nanus D.M. Renal-cell carcinoma. N Engl J Med, 1996, 335, 865–875.

    Article  PubMed  CAS  Google Scholar 

  • Nickel J.C., Fradet Y., Boake R.C., Pommerville P.J., Perreault J.P., Afridi S.K. and Elhilali M.M. (1996). Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study. Can Med Assoc J, 155,1251–1259.

    CAS  Google Scholar 

  • Oesterling J.E. (1996). Benign prostatic hyperplasia: a review of its histogenesis and natural history. Prostate, 6, 67–73.

    Article  PubMed  CAS  Google Scholar 

  • Papadopoulos I., Rudolph P., Weichert-Jacobsen K., Thiemann O. and Papadopoulou D. (1996). Prognostic indicators for response to therapy and survival in patients with metastatic renal cell cancer treated with interferon-α2β and vinblastine. Urology, 48, 373–378.

    Article  PubMed  CAS  Google Scholar 

  • Peters C.A. and Walsh P.C. (1987). The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia. N Engl J Med, 317, 599–604.

    Article  PubMed  CAS  Google Scholar 

  • Reynolds C.F. III, Frank E., Thase M.E., Houck P.R., Jennings J.R., Howell J.R., Lilienfeld S.O. and Kupfer D.J. (1988). Assessment of sexual function in depressed, impotent, and healthy men: factor analysis of a Brief Sexual Function Questionnaire for men. Psychiat Res, 24, 231–250.

    Article  Google Scholar 

  • Richie J.P., Kantoff P.W. and Shapiro C.L. (1997). Renal cell carcinoma. In Cancer Medicine, 4th edn, eds, Holland J.F., Frei E. III, Bast R.C Jr, Kufe D.W., Morton D.L. and Weichselbaum R.R., pp. 2085–2096. Baltimore, MD, Williams & Wilkins.

    Google Scholar 

  • Schally A.V. and Comaru-Schally A.M. (1997a). Hypothalamic and other peptide hormones. In Cancer Medicine, 4th edn, eds, Holland J.F., Frei E. III, Bast R.C Jr, Kufe D.W., Morton D.L. and Weichselbaum R.R., pp. 1067-1086. Baltimore, MD, Williams & Wilkins.

    Google Scholar 

  • Schally A.V. and Comaru-Schally A.M. (1997b). Rational use of agonists and antagonists of luteinizing hormone-releasing hormone (LHRH) in the treatment of hormone-sensitive neoplasms and gynecologic conditions. Adv Drug Deliv Rev, 28, 157–169.

    Article  Google Scholar 

  • Schally A.V. and Comaru-Schally A.M. (2000). Hypothalamic and other peptide hormones. In Cancer Medicine, 4th edn, eds, Holland J.F., Frei E. III, Bast R.C. Jr, Kufe D.W., Morton D.L. and Weichselbaum R.R., pp.715–729 Hamilton, Ontario, B.C. Dekker.

    Google Scholar 

  • Schally A.V., Comaru-Schally A.M., Nagy A., Kovacs M., Szepeshazi K., Plonowski A., Varga J.L. and Haimos G. (2001). Hypothalamic Hormones and cancer. Front Neuroendocrinol, 22, 248–291.

    Article  PubMed  CAS  Google Scholar 

  • Shapiro E. and Lepor H. (1995). Pathophysiology of clinical benign prostatic hyperplasia. Urol Clin North Am, 22, 285–290.

    PubMed  CAS  Google Scholar 

  • Sion-Vardi N., Kaneti J., Segal-Abramson T., Giat J., Levy J. and Sharoni Y. (1992). Gonadotropin-releasing hormone specific binding sites in normal and malignant renal tissue. J Urol, 148, 1568–1570.

    PubMed  CAS  Google Scholar 

  • Sokoloff M.H., deKernion J.B., Figlin R.A. and Belldegrun A. (1996). Current management of renal cell carcinoma. CA Cancer J Clin, 46, 284–302.

    Article  PubMed  CAS  Google Scholar 

  • Steiner M.S. (1995). Review of peptide growth factors in benign prostatic hyperplasia and urological malignancy. J Urol, 153, 1085–1096.

    Article  PubMed  CAS  Google Scholar 

  • Wise G.J. and Ostad E. (2001). Hormonal treatment of patients with benign prostatic hyperplasia: pros and cons. Curr Urol Rep, 2, 285–291.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. A. M. Comaru-Schally
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pharmacology, University of Milan, Milan, Italy

    Eugenio E. Müller

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer-Verlag Italia

About this paper

Cite this paper

Comaru-Schally, A.M. (2003). Analogs of Luteinizing Hormone-releasing Hormone in Benign Prostatic Hyperplasia and Advanced Renal Cell Carcinoma. In: Müller, E.E. (eds) Peptides and Non Peptides of Oncologic and Neuroendocrine Relevance. Springer, Milano. https://doi.org/10.1007/978-88-470-2085-6_2

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-2085-6_2

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-2170-9

  • Online ISBN: 978-88-470-2085-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation